In this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.
A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
The panelists conclude their discussion by offering future perspectives on CLL treatment, emphasizing remaining areas of unmet needs in the treatment landscape.
The expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.
This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.
Before closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.
Original research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.
The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.
Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.
In an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.
The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.
This work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.